(Q37770789)

22 August 2017

title

Tocilizumab: therapy and safety management (English)

1 reference

22 August 2017

1 reference

15

Thierry Schaeverbeke

1 reference

22 August 2017

Jacques-Eric Gottenberg

7

object named as

Jacques-Eric Gottenberg

0 references

Éric Hachulla

object named as

Eric Hachulla

10

0 references

Bruno Fautrel

5

object named as

Bruno Fautrel

1 reference

22 August 2017

6

Laure Gossec

1 reference

22 August 2017

16

Daniel Wendling

1 reference

22 August 2017

14

Alain Saraux

1 reference

22 August 2017

18

Stanislas Pol

1 reference

22 August 2017

19

Xavier Mariette

1 reference

22 August 2017

Thao Pham

1

1 reference

22 August 2017

Pascal Claudepierre

2

1 reference

22 August 2017

Arnaud Constantin

3

1 reference

22 August 2017

Michel de Bandt

4

1 reference

22 August 2017

Philippe Goupille

8

1 reference

22 August 2017

Séverine Guillaume

9

1 reference

22 August 2017

Charles Masson

11

1 reference

22 August 2017

Jacques Morel

12

1 reference

22 August 2017

Xavier Puéchal

13

1 reference

22 August 2017

Eric Bruckert

17

1 reference

22 August 2017

Jean Sibilia

20

1 reference

22 August 2017

Club Rhumatismes et Inflammation (CRI)

21

1 reference

22 August 2017

publication date

17 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

77 Suppl 1

1 reference

22 August 2017

page(s)

S3-100

1 reference

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Abatacept therapy and safety management

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Cardiovascular biology of interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Cardiovascular risk in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Patient education on cardiovascular aspects of rheumatoid disease: an unmet need

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Impact of traditional therapies and biologics on cardiovascular diseases in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA?

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

1 reference

7 January 2021

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Erratum to 'The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting' [J. Clin. Virol. 41 (4) 2008 243-254].

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Tocilizumab for multirefractory adult-onset Still's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interleukin-6 and its receptor in cancer: implications for translational therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Cytokine-based transformation of immune surveillance into tumor-promoting inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Proliferation of human non-small-cell lung cancer cell lines: role of interleukin-6

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Systematic review of the association between circulating interleukin-6 (IL-6) and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interleukin-6 treatment augments cutaneous wound healing in immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Essential involvement of IL-6 in the skin wound-healing process as evidenced by delayed wound healing in IL-6-deficient mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Vaccine responses in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

1 reference

7 January 2021

Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interleukin 6: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interleukin-6 inhibits early differentiation of ATDC5 chondrogenic progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Preliminary definition of improvement in juvenile arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interleukin-6 signalling in juvenile idiopathic arthritis is limited by proteolytically cleaved soluble interleukin-6 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody.

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Soluble intercellular adhesion molecule 1 in spondylarthropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Interleukin-6 serum concentration in ankylosing spondylitis: a reliable predictor of disease progression in the subsequent year?

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1297-319X%2810%2970001-4

7 January 2021

10.1016/S1297-319X(10)70001-4

Identifiers

DOI

1 reference

22 August 2017

1 reference